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Abstract
AIM: To investigate large tumor suppressor 1 (LATS1) 
expression, promoter hypermethylation, and microsat-
ellite instability in colorectal cancer (CRC).
METHODS: RNA was isolated from tumor tissue of 
142 CRC patients and 40 colon mucosal biopsies of 
healthy controls. After reverse transcription, quantita-
tive polymerase chain reaction (PCR) was performed, 
and LATS1  expression was normalized to expression of 
the ACTB and RPL32  housekeeping genes. To analyze 
hypermethylation, genomic DNA was isolated from 44 
tumor CRC biopsies, and methylation-specific PCR was 
performed. Microsatellite instability (MSI) status was 
checked with PCR using BAT26, BAT25, and BAT40 
markers in the genomic DNA of 84 CRC patients, fol-
lowed by denaturing gel electrophoresis.
RESULTS: Decreased LATS1  expression was found in 
127/142 (89.4%) CRC cases with the average ratio 
of the LATS1 level 10.33 ± 32.64 in CRC patients vs  
32.85 ± 33.56 in healthy controls. The lowest expres-
sion was found in Dukes’ B stage tumors and G1 (well-
differentiated) cells. Hypermethylation of the LATS1  
promoter was present in 25/44 (57%) CRC cases ana-
lyzed. LATS1  promoter hypermethylation was strongly 
associated with decreased gene expression; methylat-
ed cases showed 162× lower expression of LATS1  than 
unmethylated cases. Although high-grade MSI (muta-
tion in all three markers) was found in 14/84 (17%) 
cases and low-grade MSI (mutation in 1-2 markers) 
was found in 30/84 (36%) cases, we found no associa-
tion with LATS1  expression.
CONCLUSION: Decreased expression of LATS1  in CRC 
was associated with promoter hypermethylation, but 
not MSI status. Such reduced expression may promote 
progression of CRC.
© 2013 Baishideng. All rights reserved.
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instability; Salvador-Warts-Hippo pathway
Core tip: Searching for new colorectal cancer (CRC) 
molecular markers is a very important objective, be-
cause CRC is one of the most common malignancies 
in the world and one of the most fatal of human neo-
plasms. Decreased expression of large tumor suppres-
sor 1 in CRC was associated with promoter hypermeth-
ylation, but not microsatellite instability status. Such 
reduced expression may promote progression of CRC.
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INTRODUCTION
Colorectal cancer (CRC) is one of  the most common ma-
lignancies in the world and one of  the most fatal human 
neoplasms. Almost 1.2 million new cases occur annually, 
accounting for 608700 related deaths in 2008[1]. Although 
nearly 90% of  patients may be successfully cured with 
surgery in early stages, CRC is frequently diagnosed in 
late stages, i.e., Dukes’ C and D, when the prognosis is 
poor[2,3]. Therefore, the search for CRC molecular mark-
ers, as well as elucidation of  epigenetic factors that are 
responsible for variability in the expression of  putative 
markers, is very important.
Human large tumor suppressor 1 (LATS1, also 
known as WARTS) was discovered in 1999[4] as a highly 
conserved homolog of  the Drosophila melanogaster (D. me-
lanogaster) lats gene[5]. LATS1 encodes a serine/threonine 
kinase, which is involved in the regulation of  various 
cellular processes. Before mitotic division, the presence 
of  LATS1 is crucial for control of  the R1 tetraploidy 
checkpoint[6]. During the early phase of  mitosis, LATS1 
associates with cell division control protein 2 homolog[7], 
and the progress of  cytokinesis occurs only after associa-
tion of  the MOB kinase activator 1A cytoplasmic protein 
with LATS1[8,9].
More recently, genetic studies in Drosophila have iden-
tified LATS as a central mediator in a tumor suppress-
ing pathway called the Salvador-Warts-Hippo (SWH) 
pathway[10,11]. The SWH pathway is also a critical factor in 
the regulation of  organ size in D. melanogaster and mam-
mals[12,13]. Moreover, deregulation of  SWH pathway activ-
ity has been implicated in the genesis of  multiple human 
cancers[11,14-16]. Several mammalian factors are involved 
in signal transduction in the SWH pathway, including 
the tumor suppressor proteins neurofibromin 2, Ras as-
sociation family member 1-6, serine/threonine kinase 3, 
LATS1, and an oncogene called Yes-associated protein 
(YAP). YAP, a transcription coactivator that associates 
with various transcription factors, is overexpressed in 
human carcinomas including ovarian, liver, and prostate 
cancers[13]. LATS1 kinase is a main negative regulator of  
YAP. LATS1 inhibits the transcriptional activity/function 
of  YAP via phosphorylation of  Ser 127 in YAP[17]. More-
over, LATS1-phosphorylated YAP is involved in a p53-
independent apoptosis pathway in which phosphorylated 
YAP plays a role in transcriptional activation of  the pro-
apoptotic gene, p53 up-regulated modulator of  apopto-
sis[18]. Overexpression of  LATS1 in LATS1-/- mouse cells 
(by introducing human LATS1 with adenovirus-mediated 
gene transfer) and HeLa cells suppresses tumorigenicity 
in vivo and in vitro by inducing apoptosis[18,19].
LATS1 is considered to play a suppressor role in 
some tumors. Decreased LATS1 expression is found 
mainly in soft tissue-derived tumors, including sarco-
mas[20] and astrocytomas[21]. However, LATS1 quiescence 
was also observed in breast[22], cervical[23] cancers and 
head and neck squamous cell carcinoma[24]. In the gastro-
intestinal tract, decreased LATS1 expression has been re-
cently observed in gastric cancer[25], but in a small sample 
of  CRCs, LATS1 overexpression was found[26].
Hypermethylation of  CpG islands (GC-rich se-
quences) in regulatory portions of  a gene is an important 
epigenetic mechanism responsible for decreased gene 
expression or gene silencing[27-30]. Aberrant methylation 
of  CpG islands in the promoter region of  LATS1 has 
been found in breast and ovarian cancers[4,22,31] and soft-
tissue sarcomas[20]. Our preliminary results suggested that 
LATS1 expression is decreased in CRC and is associated 
with promoter hypermethylation[32]. In the present study, 
we used quantitative polymerase chain reaction (QPCR) 
to determine the expression profile of  LATS1 in a rela-
tively large group of  CRC patients. We also examined the 
hypermethylation status of  the LATS1 promoter as a 
putative epigenetic mechanism affecting gene expression. 
MATERIALS AND METHODS
Patients
The study was approved by the local ethics committees, 
and informed, written consent regarding the use of  tis-
sue was obtained before surgery or colonoscopy from all 
CRC and control patients, respectively. The specimens 
were obtained from four gastrointestinal endoscopic 
units and surgical clinics located in geographically differ-
ent parts of  Poland from 2008 to 2011. Clinical and de-
mographic data were collected at the time of  enrollment 
(Table 1). The study included 142 patients with CRC (87 
males and 55 females; mean age 68 ± 10.8 years; range, 
37-90 years). No CRC patients had a second neoplastic 
disease. None of  the patients had undergone previous 
chemo- or radiotherapy. Tumors located in the anal canal 
and anus were not included in this study. The control 
group comprised 40 healthy individuals (17 males and 23 
females; mean age 53 ± 14.2 years; range, 21-76 years) 
who underwent colonoscopy as part of  routine surveil-
lance for CRC. None of  the CRC patients or controls 
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suffered from inflammatory bowel disease or had a family 
history of  CRC. Patients were not on medication at the 
time of  investigation. Before medical examination, blood 
samples were collected for routine testing from all CRC 
patients. 
Collection of colon samples
All steps of  material collection, including patients’ clinical 
data, tissue collection, storage, shipment, and laboratory 
processing, followed The Cancer Genome Atlas (TCGA) 
instructions and were standardized in all collaborative clin-
ics[33,34]. Briefly, CRC samples were obtained during surgical 
hemicolectomy, and control group specimens were collect-
ed during colonoscopy. For histopathologic examination 
and molecular studies, samples (5 mm × 5 mm × 5 mm) 
from macroscopically altered tumor tissue were taken 
within 20 min after tumor resection. For control patients, 
one biopsy (2 mm × 2 mm × 2 mm) was fixed in 10% 
neutral buffered formalin, and two specimens from the 
adjacent location to the biopsy site were collected for 
nucleic acid analyses. The formalin-fixed samples were 
obtained for the routine histological survey; if  the result 
of  histological examination showed pathological condi-
tion of  the patient’s tissue, the adjacent biopsies were 
excluded from the control group analyzed in this study. 
Both tumor samples and mucosal biopsies were immedi-
ately placed in sterile vials containing RNAlater (Ambion-
Life Technologies, Grand Island, NY, United States), 
incubated for 6 h at 4 ℃, and then stored at -25 ℃ until 
further analysis.
Nucleic acid extraction and reverse transcription 
Total RNA was extracted from a portion of  the tumor 
samples (ca. 3 mm × 5 mm × 5 mm) and the entire mu-
cosal biopsies of  control patients using a Total RNA kit 
(A&A Biotechnology, Gdynia, Poland). Isolated RNA 
was quantified with spectrophotometry (Nanodrop ND 
1000, Thermo Fisher Scientific, Fitchburg, WI, United 
States). DNA was digested with RNase-free DNase I 
(Fermentas-Thermo Fischer Scientific, Fitchburg, WI, 
United States) for 30 min at 37 ℃. Then, the DNase was 
inactivated by adding EDTA and incubating at 65 ℃ 
for 10 min. Before storing at -85 ℃, RNA integrity was 
analyzed with agarose gel electrophoresis. Total RNA 
(2 μg) was reverse transcribed using 0.5 μg oligo(dT)18 
primers (Sigma-Aldrich, Munich, Germany) and 200 U 
RevertAid M-MuLV Reverse Transcriptase (Fermentas-
Thermo Fischer Scientific, Fitchburg, WI, United States) 
in a total volume of  20 μL, and the resulting cDNA was 
stored at -25 ℃. In 84 of  the CRC cases, 1 mL venous 
blood that was collected in sterile K2-EDTA vials was 
used for DNA isolation using a Blood Mini DNA kit 
(A&A Biotechnology, Gdynia, Poland). From these same 
patients, DNA was also extracted from a portion of  the 
tumor samples (ca. 3 mm × 5 mm × 5 mm) adjacent to 
the tumor fragments used for the RNA study using the 
Genomic Mini AX Tissue kit (A and A Biotechnology, 
Gdynia, Poland) and stored at -25 ℃. 
QPCR assay to determine the LATS1 mRNA level
Quantification of  LATS1 gene expression was carried 
out using iQ Cycler (Bio-Rad, Hercules, CA, United 
States) with Sybr®Green I as a fluorophore. LATS1 ex-
pression was determined with Livak’s comparative meth-
od 2-ΔΔCt[35] relative to the geometric mean of  the expres-
sion levels of  two housekeeping genes: β-actin (ACTB; 
GenBank acc. No. NM_001101.3) and ribosomal protein 
L32 (RPL32; NM_000994.3). These genes showed very 
stable expression in CRC in our previous studies[36,37] and 
studies of  other investigators[38]. Except for the ACTB 
assay[39], all primers were designed by us using GenBank 
data. QPCR conditions were validated and showed 
90%-100% efficiency for all assays. The amplification 
primer pairs were 5’-TGCACTGGCTTCAGATGGA-
CAC-3’ and 5’-ATGTGCTAGACATCGCTGGTGC-3’; 
for LATS1 (functional transcript, ENSEMBL No. 
ENST00000543571, GenBank No. NM_004690.2), 
5’-TGTGCCCATCTACGAGGGGTATGC-3’ and 
5’-GGTACATGGTGGTGCCGCCAGACA-3’ for 
ACTB[39], and 5’-TGACAACAGGGTTCGTAGAA-
GAT-3’ and 5’-GTTCTTGGAGGAAACATTGT-
GAG-3’ for RPL32. The reaction mixture (17 μL) includ-
ed 0.4 μL cDNA, 0.2 μmol/L each forward and reverse 
primers, and real-time PCR iQ SYBR Green SuperMix 
(Bio-Rad). All reactions were performed in duplicate. The 
amplification parameters were denaturation for 5 min at 
95 ℃, followed by 38 cycles of  denaturation for 15 s at 
95 ℃, annealing for 20 s at 55 ℃ for RPL32, 57 ℃ for 
LATS1, and 60 ℃ for ACTB, extension for 15-25 s at 
72 ℃, and fluorescence reading for 5 s at 77 ℃-80 ℃. 
Dynamic melting curve analysis was performed for all 
reactions. Data were automatically collected and analyzed 
with iCycler iQ Optical Software ver. 3.0a (Bio-Rad).
Microsatellite instability status analysis
Microsatellite instability (MSI) status was determined ac-
cording to the National Cancer Institute Workshop on 
Microsatellite Instability for Cancer Detection and Fa-
milial Predisposition[40] and was based on polymorphism 
analysis of  three markers: BAT26 for MSH2, BAT25 for 
the c-kit oncogene, and BAT40 for the HSD3B2 suppres-
sor gene. BAT sequences were obtained from the UniSTS 
database (http://www.ncbi.nlm.nih.gov/unists), and the 
methodology was based on our previous results[41]. Brief-
ly, the PCR reaction contained 0.5 U Taq polymerase, 
PCR buffer (Fermentas-Thermo Fischer Scientific, 
Fitchburg, WI, United States), 200 nmol/L each primer 
pair, 0.1 mmol/L each dNTP, and 30 ng DNA in a final 
volume of  15 μL and was performed using the follow-
ing parameters: denaturation for 5 min at 95 ℃, 35 cycles 
of  denaturation for 15 s at 95 ℃, annealing for 20 s at 49 ℃ 
(BAT25, BAT26) or 54 ℃ (BAT40), and extension for 30 s 
at 72 ℃. Denaturing acrylamide gel electrophoresis was 
performed in a Sequi-Gen Ⅱ Sequencing Cell (Bio-Rad) 
followed by silver staining (AgNO3; POCH, Gliwice, Po-
land) for identification of  extra DNA bands, which were 
considered mutations in the selected BAT markers. Low- 
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The statistical analyses were performed using Statistica 
ver. 10 program (Stat Soft Inc., Tulsa, OK, United States), 
and the level of  significance was set at P < 0.05. 
RESULTS
Relationship between LATS1 expression and clinical 
parameters
Clinico-pathological data including tumor stages ac-
cording to tumor location, Dukes’ classification, and G 
grade[42,43] are presented in Table 1. We found no statisti-
cal differences in geographic location of  patients, sex, 
age, tumor location, and disease progression. We found 
a relationship between tumor location and erythrocyte 
counts, hematocrit level, and hemoglobin concentration; 
patients with a tumor on the right side were characterized 
by decreased values compared with patients whose tumor 
was on the left side (P < 0.05, Table 1). No associations 
between blood parameters and Dukes classification, 
TNM, and G grading of  CRC were found.
Quantification of  LATS1 mRNA was performed in 
colorectal tumor samples from 142 CRC patients and 
compared with tissue samples from 40 healthy persons. 
Decreased LATS1 gene expression was found in 127 of  
142 (89.4%) tumors in the CRC cases (P < 0.05). Because 
QPCR data were not normally distributed (mean values: 
10.33 ± 32.64 vs 32.85 ± 33.56, P < 0.05), the median 
expression ratio was 0.075 (range, 0.003-210.672) in CRC 
patients vs 40.097 (range, 0.004-98.228) in controls (P < 
0.05). Thus, the average expression of  LATS1 was many 
times lower in tumor tissue than in normal colon mucosa 
of  controls. No correlations between LATS1 mRNA lev-
el and gender, age, or tumor location were found. Also, no 
statistical differences in the mRNA ratio were observed in 
patients who lived in different regions of  Poland.
Comparison of  LATS1 expression levels with pa-
tients’ clinico-pathological data revealed 8 times lower 
LATS1 levels in Dukes’ A stage compared to controls 
(Figure 1). The lowest LATS1 expression was observed 
in Dukes’ B stage, which was 42 times lower than in con-
trols, whereas in more advanced CRC cases described as 
Dukes’ C and D stage, LATS1 expression was 24 and 
14 times lower than in controls, respectively. We found 
a weak negative correlation between tumor progres-
sion and the LATS1 mRNA level (R2 = -0.25, P < 0.05, 
Spearman’s test, plot not shown). When the histological 
G grade of  cancer cells was considered, LATS1 mRNA 
levels were significantly decreased in both G2 and G3 
grades (Figure 1). However, due to the low number of  
G1 cases (well-differentiated cells) and G4 (undifferenti-
ated cells) cases (three each), no comparison with grades 
G2 and G3 was possible.
MSI status and clinicopathological data
We analyzed 84 of  the 142 CRC cases for MSI status. The 
highest rate of  mutation was found in the BAT26 marker 
(n = 28/84; 33%), followed by 26 cases for BAT40 (31%) 
and 25 for BAT25 (30%) (Table 1). Our analysis revealed 
and high-grade MSI (MSI-L and MSI-H, respectively) 
were confirmed by 1-2 and all 3 mutated markers, respec-
tively. If  no mutation was observed in the paired tumor 
and blood DNA samples, the sample was confirmed as 
microsatellite stable (MSS). 
Bisulfite modification and methylation-specific PCR
Because the method of  bisulfite conversion of  DNA 
requires at least 1 μg DNA, we performed this analysis 
with only 44 tumor samples with sufficient material us-
ing the EZ DNA MethylationTM kit (Zymo Research, 
Orange, CA, United States). Briefly, 1 μg tissue DNA 
was denatured using 0.2 mol/L NaOH and subsequently 
incubated with a sodium salt of  bisulfite ion (HSO3-) at 
50 ℃ for 16 h. Next, the mixture was desulfonated, and 
DNA was purified on silica-membrane columns to a final 
volume of  10 μL. Bisulfite-modified DNA was stored at 
-25 ℃. The methylation status of  the LATS1 promoter 
region was determined with methylation-specific PCR 
(MSPCR). Bisulfite-modified DNA was amplified with 
primers specific for methylated or unmethylated sequenc-
es. The methylated DNA was amplified using M prim-
ers: sense 5’-TCGTTTTGTCGTTTAGGTTGG-3’ and 
antisense 5’-CGACGTAATAACGAACGC-3’, and un-
methylated DNA was amplified using UM primers: sense 
5’-TAGGTTGGAGTGTGGTGGT-3’ and antisense 
5’-CCCAACATAATAACAAACACCT-3’. All primer 
sequences were previously published[20-22] except for the 
M sense primer, which was redesigned de novo using the 
GenBank database and methPrimerDB online software. 
For the methylation assay, Human HCT116 DKO Non-
methylated DNA and Human HCT116 DKO Methyl-
ated DNA (Zymo Research) after bisulfite modification 
were used as positive controls in MSPCR. Briefly, 0.6 μL 
bisulfite-modified DNA was amplified in a total volume 
of  15 μL containing reagents from the ZymoTaq™ 
DNA Polymerase kit (Zymo Research) and 400 nmol/L 
each primer. MSPCR reactions were as follows: denatur-
ation for 5 min at 95 ℃, five cycles of  denaturation for 
30 s at 95 ℃, annealing for 30 s at 52 ℃, extension for 20 
s at 72 ℃; 30 cycles of  denaturation for 30 s at 95 ℃, an-
nealing for 30 s at 50 ℃, extension for 20 s at 72 ℃; final 
extension for 5 min at 72 ℃. PCR products (10 μL) were 
run on a 2% agarose gel, stained with ethidium bromide, 
and visualized under ultraviolet illumination. Images were 
stored using a Gel Doc apparatus and software (Bio-Rad).
Statistical analysis
Normality of  the QPCR data was assessed with the 
Shapiro-Wilk test. Parametric data such as red blood 
cells, hematocrit, hemoglobin, and LATS1 mRNA levels 
between various groups were evaluated using the Mann-
Whitney U test. Comparison of  LATS1 mRNA ratios 
between CRC subgroups with various histological and 
MSI grades and methylation status was calculated using 
the Kruskal-Wallis analysis of  variance (ANOVA) test. 
Fisher’s exact test was used to assess correlations between 
the methylation status and clinical-pathological variables. 
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expression level was 305 times lower in methylated CRC 
samples than in unmethylated samples (P < 0.05, plot not 
shown). The lowest LATS1 ratio was found in Dukes’ 
D stage (1263 times lower than in control). However, we 
found that all analyzed samples in this subgroup showed 
a hypermethylation pattern, and thus, statistical compari-
son between methylated and unmethylated cases in D 
stage could not be evaluated. Interestingly, LATS1 ex-
pression in unmethylated CRC cases was not statistically 
different from that in controls.
When the methylation status of  the LATS1 promoter 
was analyzed in patients with and without the presence 
of  metastatic cells in regional lymph nodes and/or dis-
tant organs, we found a strong relationship between the 
metastatic potency of  cancer and reduced expression 
of  LATS1 and hypermethylation of  its promoter. The 
LATS1 ratio was 381 times lower in hypermethylated vs 
unmethylated in metastatic CRC cases (P < 0.05, dark 
grey boxes in Figure 3, Table 2), and only 8 times lower in 
hypermethylated vs unmethylated in non-metastatic CRC 
cases (P < 0.05, light grey boxes in Figure 3, Table 2). 
Moreover the expression of  LATS1 in unmethylated met-
astatic CRC samples was 49 times reduced as compared to 
unmethylated non-metastatic CRC cases (P < 0.05, Figure 
3, Table 2).
Comparison of  the histological grading of  CRC (G), 
methylation status, and LATS1 mRNA levels revealed 
the highest proportion of  hypermethylation (71% of  
analyzed cases) in poorly differentiated (G3) CRC cases 
(Table 2). However, the difference in the LATS1 expres-
sion level in methylated cases was only ca. 4 times lower 
than in unmethylated cases in the G3 subgroup (P < 0.05, 
Table 2, Figure 4). On the contrary, the difference in the 
LATS1 mRNA level between methylated and unmethyl-
  Clinical parameter Total M Av. LATS1 mRNA fold UM Av. LATS1 mRNA fold Av. LATS1 mRNA fold P  value between 
change, control vs  M change,  control vs  UM change, UM vs  M UM and M groups
  Tumor total 44 25 (57)   597 19          3.55 162     0.00005
  Dukes’ stage A   4   4 (100)   556   0 No data No data -
B 16   5 (31)   699 11 228     3 0.041
C 19 11 (58)   469   8          1.53 305 0.009
D   5   5 (100) 1263   0 No data No data -
  Lymph node 
  metastasis
Negative 20   9 (45)   632 11   75     8 0.015
Positive 24 16 (67)   586   8          1.53 381   0.0002
  Histological 
  differentiation G stage
G1   2   1 (50)   801   1 538        1.5 NS
G2 11   3 (27) 1216   8        1.5 802 0.018
G3 28 20 (71)   538   8 166          3.65 0.015
G4   3   1 (33)   699   2   92     8 NS
  MSI status MSS 27 19 (70)       7   8        1.7     4 NS
MSI-L 11   7 (64)       8   4        2.4        3.3 NS
MSI-H   6   4 (67)     12   2        3.5        3.4 NS
Table 2  Relationship between large tumor suppressor 1 promoter methylation status, large tumor suppressor 1 mRNA level, and 
histopathological and microsatellite instability data in colorectal cancer  n  (%)
M: Hypermethylation of large tumor suppressor 1 (LATS1) promoter; UM: Unmethylation of LATS1 promoter; MSI: Microsatellite instability; MSS: Micro-
satellite stable; MSI-L: Low grade MSI, mutation in 1-2 BAT markers; MSI-H: High grade MSI, mutation in 3 BAT markers; NS: Noy significant.
Control     Dukes' A     Dukes' B     Dukes' C    Dukes' D        G1             G2            G3             G4
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Figure 1  Large tumor suppressor 1 mRNA levels in colorectal cancer and control colon biopsies. Quantitative polymerase chain reaction results of large tumor 
suppressor 1 (LATS1) expression in 142 colorectal cancer (CRC) samples compared with 40 colon biopsies of healthy patients. CRC cases were divided according 
to clinicopathological data: tumor stage - Dukes’ A (n = 27), B (n = 41), C (n = 54), D (n = 20); histological differentiation of tumor cells (G staging): G1 (n = 3), G2 (n = 
48), G3 (n = 88), G4 (n = 3). Vertical bars represent LATS1 fold ratio calibrated to the average Ct of control (ΔΔCtLATS1 = ΔCtLATS1, sample - ΔCtLATS1, control), error bars: SE. aP 
< 0.05 vs control group; cP < 0.05 between subgroups (Mann-Whitney U test). 
Wierzbicki PM et al . LATS1 hypermethylation and underexpression in CRC
4369 July 21, 2013|Volume 19|Issue 27|WJG|www.wjgnet.com
ated CRC tissue was much more pronounced in moder-
ate-differentiated G2 cells (P < 0.05, Figure 4). Moreover, 
the LATS1 ratio in G2 unmethylated cases was not sta-
tistically different from that in control healthy patients. 
Interestingly, G3 unmethylated cases showed much lower 
(ca. × 100) LATS1 expression than G2 unmethylated 
biopsies (P < 0.05, Figure 4). Finally, we did not observe 
any statistically significant correlation between G grading 
and the LATS1 mRNA level or hypermethylation of  its 
promoter. 
When we focused on MSI and the LATS1 methyla-
tion status, we did not find any significant relationship 
because the statistical distribution of  the results was very 
broad (Table 2, figure not shown). Most methylated cases 
(27/44) were considered MSS with no significant differ-
ence between methylated and unmethylated cases. MSI-L 
and MSI-H samples were also characterized as having 
relatively small differences in LATS1 expression between 
methylated and unmethylated cases. 
DISCUSSION
LATS1 is a tumor suppressor gene involved in several 
important mitotic processes, which are crucial in the de-
velopment of  CRC[7,44]. The most recent data suggest that 
the SWH pathway may play a very important role in CRC 
progression[45]. LATS1 is a key transducer of  this pathway, 
and reduced expression of  LATS1 is connected with de-
regulation of  SWH, thus activating the YAP oncogene[18]. 
Moreover, p53, a “genome guardian” protein, is indirectly 
regulated by LATS1[46]. MDM2, the regulator of  p53 
ubiquitination, is sequestered by native cellular LATS1, 
so that in the case of  reduced LATS1 expression, degra-
dation of  p53 cannot be triggered by MDM2[46]. Those 
observations suggest that studies on the role of  LATS1 
in CRC should be intensified. Our investigation provides 
the first analysis of  the LATS1 expression profile in a 
relatively large group of  CRC patients compared with 40 
healthy persons as well as analysis of  LATS1 promoter 
hypermethylation as a putative quiescence factor for 
LATS1 expression in CRC. The results of  our quantita-
tive study, which demonstrated decreased LATS1 expres-
sion in 89% of  CRC patients, are consistent with the 
decreased LATS1 expression found in other tumors[20-22]. 
However, Bianchini et al[26] reported 3.11-fold increased 
expression of  LATS1 in 25 CRC patients compared 
with 13 non-cancerous adjacent tissue samples from the 
surgical margin. This discrepancy may be due to impor-
tant methodological differences between the two studies. 
First, Bianchini et al[26] compared their CRC data to 13 
non-cancerous adjacent tissue samples from the surgical 
margin, whereas in our study of  142 CRC (Dukes’ stages 
A-D) patients, the histologically normal mucosa of  40 
healthy controls was used as a reference sample. Second, 
Bianchini et al[26] used the microarray technique to gener-
ate expression profiles of  19200 different transcripts nor-
malized to glyceraldehyde 3-phosphate dehydrogenase 
expression in only Dukes’ B and C stage CRC patients. 
Seven transcripts are generated from LATS1 (Ensembl 
database), however, Bianchini et al[26] did not specify the 
isoform they analyzed. Our QPCR assay was designed 
to amplify the functional isoform of  LAST1 that was 
also analyzed in other tumors[20-22]. Hence, our data can-
not be directly compared with the contradictory results 
of  Bianchini et al[26]. Moreover, we are not aware of  any 
other reports suggesting increased LATS1 expression in 
cancer. Immunohistochemical analysis of  LATS1 protein 
expression in gastric cancer revealed lower expression 
Figure 2  Microsatellite instability status and large tumor suppressor 1 
expression. Comparison of large tumor suppressor 1 (LATS1) mRNA levels 
in cases divided by the mutations observed in the BAT26, BAT25, and BAT40 
microsatellite markers. Samples were considered to have microsatellite stability 
(MSS; no mutation), microsatellite instability-low grade (MSI-L; 1-2 mutations, 
light grey box), and microsatellite instability-high grade (MSI-H; mutations in all 
three markers, dark grey box). MSS (n = 40), MSI-L (n = 30), MSI-H (n = 14). 
Vertical bars represent LATS1 fold ratio calibrated to the average Ct of MSS 
cases - (ΔΔCtLATS1 = ΔCtLATS1, MSI - ΔCtLATS1, MSS), error bars: SE.
Figure 3  Large tumor suppressor 1 expression in colorectal cancer in 
relation to promoter methylation status. Comparison between large tumor 
suppressor 1 (LATS1) mRNA expression and epigenetic hypermethylation (M) or 
absence of hypermethylation (UM) of CpG islands located within the LATS1 pro-
moter region in a total of 44 colorectal cancer (CRC) cases (black vertical bars, 
n = 25 for M and n = 19 for UM). Vertical bars represent the LATS1 fold ratio 
calibrated to the average Ct of control (ΔΔCtLATS1 = ΔCtLATS1, sample - ΔCtLATS1, control), 
error bars: SE. CRC cases were further divided into two subgroups: absence or 
presence of metastasis in lymph nodes/distant organs: N0M0: Light grey bars (n 
= 20; M: n = 9; UM: n = 11); N1-2/M0-1: Dark bars (n = 24; M: n = 16; UM: n = 8), 
respectively. aP < 0.05 vs control group; cP < 0.05 between subgroups (Mann-
Whitney U test).
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levels in 40 of  78 tumor lesions compared with normal 
gastric mucosa. The expression of  LATS1 protein was 
significantly lower in gastric cancer with lymph node me-
tastases than in cases without lymph node involvement[25]. 
Furthermore, in a group of  117 breast cancer patients, 
LATS1 mRNA was significantly decreased in the tumor 
tissue, and its decreased level was associated with a large 
tumor size, high lymph node metastasis rate, and poor 
prognosis[22]. In 30 astrocytoma cases, the level of  LATS1 
was 2-10 times lower as quantified by QPCR compared 
with 10 samples from normal brain tissue[21]. The most 
recent data showed that reduced expression of  LATS1 
was correlated with the occurrence of  metastatic glioma 
and poor survival of  patients in a group of  17 cases[47]. 
Hence, decreased expression of  LATS1 in tumor tissue 
may suggest a suppressor role in CRC and other tumors. 
MSI status has been regarded as one of  the most im-
portant genetic markers and is strongly associated with 
molecular data, clinical findings, medical treatment, and 
patient outcome[48,49]. Our finding based on three BAT 
markers showed that more than half  of  the CRC patients 
had MSI tumors. Because we obtained samples from vari-
ous clinics in different locations in Poland, our findings 
add to the observations by Smigiel et al[50] who observed 
MSI-L and MSI-H in 20% and 20.1% of  cases, respec-
tively, in a group of  143 CRC patients in the Lower Silesia 
region, which was not included in our analysis. The MSI 
phenotype may affect expression patterns of  different 
proteins[51], and thus, we tried to estimate if  decreased 
expression of  LATS1 was associated with MSI. Our find-
ings excluded MSI-L and MSI-H as factors that may affect 
LATS1 expression in the studied sample of  CRC patients.
Inactivation of  a typical tumor suppressor gene is 
generally induced by epigenetic factors such as mutation 
of  one allele and/or loss of  heterozygosity (LOH) of  the 
other allele[52,53] or hypermethylation of  CpG islands in 
the regulatory region of  the gene[27-30]. Such factors may 
lead to a complete loss of  gene function in cancer[54,55]. 
Expression of  the LATS1 transcript can be epigenetical-
ly decreased by hypermethylation of  CpG islands located 
within the 5’ upstream regulatory region of  the gene[20-22]. 
Because LATS1 was reduced in several malignancies, 
we decided to assess the hypermethylation status of  the 
LATS1 CpG island. Our study is the first report of  the 
hypermethylation status of  LATS1 in CRC, showing 
an association between hypermethylation and decreased 
LATS1 expression. LATS1 hypermethylation was ob-
served in 17/30 (56%) breast cancers and was associated 
with decreased LATS1 expression; methylated cases 
showed a 3-fold decreased expression compared with un-
methylated cases[22]. LATS1 hypermethylation was found 
in 13/54 (24%) cases of  head and neck cancer[24] and in 
64% (56/88) of  astrocytomas[21]. Moreover, in astrocyto-
mas, the methylation status was associated with decreased 
LATS1 expression[21]. A similar relationship between de-
creased LATS1 expression and its hypermethylation was 
observed in our study in 57% of  analyzed CRC cases. 
Interestingly, other known epigenetic factors do not seem 
to be involved in reduced LATS1 expression in can-
cer. In a group of  25 breast cancers, LOH at 6q24-25.1 
(LATS1 locus) was found in only one case (4%), whereas 
no mutation was found and only two gene polymor-
phisms were observed. However, neither polymorphism 
caused amino acid substitution[31]. As further support 
that hypermethylation may be the major epigenetic fac-
tor in LATS1 silencing, the expression of  LATS1 in the 
P- Reviewers  Bener A    S- Editor  Wen LL    L- Editor  Cant MR    E- Editor  Li JY 
P- Reviewers  Bener A    S- Editor  Song XX    L- Editor  Stewart GJ    E- Editor  Li JY
Figure 4  Methylation status of large tumor suppressor 1 in relation to the expression ratio and histological staging of cells. Forty-four colorectal cancer 
cases were classified according to histological examination: G1: Well-differentiated cells, n = 2 (light grey bars), G2: Moderately differentiated cells, n = 11 (grey 
bars), G3: Poorly differentiated cells, n = 28 (dark grey bars), G4: Undifferentiated cells, n = 3 (black bars). G1 epigenetic hypermethylation (M) (n = 1), G1 absence 
of hypermethylation (UM) (n = 1), G2 M (n = 3), G2 UM (n = 8), G3 M (n = 20), G3 UM (n = 8), G4 M (n = 1), G4 UM (n = 2). Vertical bars represent the large tumor 
suppressor 1 (LATS1) fold ratio calibrated to the average Ct of control (ΔΔCtLATS1 = ΔCtLATS1, sample - ΔCtLATS1, control), error bars: SE. aP < 0.05 vs control group; cP < 0.05 
between subgroups (Mann-Whitney U test).
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hypermethylated cell lines U251 (an established glioma 
cell line) and SHG-44 (a human malignant glioma cell 
line) was restored by addition of  5-aza-deoxycytidine, and 
apoptosis of  cancer cells results[21]. 
Decreased expression of  LATS1 that is associated 
with promoter hypermethylation may contribute to sup-
pression of  the SWH pathway[10,11,13,18]. This pathway 
is prone to deregulation because few proteins involved 
in signal transduction are both tumor suppressors and 
oncoproteins. Altered expression of  YAP, RASSF1A, 
LATS1, and MST2 in cancer cell lines leads to higher 
resistance of  the cells to apoptosis[10,13,17,18]. Moreover, re-
duced expression of  other genes that are not directly in-
volved in the SWH pathway, such as WW and C2 domain 
containing 1 (KIBRA) and salvador homolog 1 (SAV1), 
may contribute to the quiescence of  this pathway[11,16,56]. 
Such suppression of  the SWH pathway is related to 
epithelial-to-mesenchymal transition features and poor 
prognosis in breast cancer[16]. 
In conclusion, this is the first study to show decreased 
expression of  LATS1 in CRC, confirming its tumor sup-
pressor function and linking its downregulation to the epi-
genetic hypermethylation of  the LATS1 promoter region.
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Background
Searching for new colorectal cancer (CRC) molecular markers is a very impor-
tant objective, because CRC is one of the most common malignancies in the 
world and one of the most fatal of human neoplasms. The molecular mecha-
nisms of CRC are still unknown, but deregulation of mitotic division as well as 
apoptosis resistance are clearly associated with CRC progression.
Research frontiers
Human large tumor suppressor 1 (LATS1) encodes a serine/threonine kinase, 
which mediates a tumor suppressor pathway called the Salvador-Warts-Hippo 
(SWH) pathway. Abnormal expression of LATS1 was observed in some tumors, 
and its expression in CRC has not been analyzed quantitatively.
Innovations and breakthroughs
This is the first study of a large group of CRC patients that shows quantitatively 
reduced LATS1 expression at the mRNA level. Decreased levels of LATS1 
were strongly associated with hypermethylation of its promoter, particularly in 
metastatic tumors. 
Applications
With knowledge regarding the decreased expression of LATS1 in CRC, focus-
ing on its intracellular signaling pathways in CRC and the probable involvement 
of this gene in CRC pathogenesis as a molecular marker may be possible.
Terminology
LATS1 is a putative tumor suppressor gene that shows reduced expression in 
several malignancies. LATS1 is important in karyo- and cytokinesis and is part 
of the SWH pathway. Hypermethylation of the LATS1 promoter is a common 
epigenetic factor responsible for downregulation and silencing of this gene.
Peer review
The authors collected and processed samples of CRC tumors and control colon 
biopsies from four collaborative clinics from four different regions of Poland. 
Molecular quantitative assays based on quantitative polymerase chain reaction 
revealed strongly reduced expression of LATS1 in CRC tumors. Furthermore, 
this downregulation was strongly associated with the occurrence of hyper-
methylation of the LATS1 promoter but not with microsatellite instability. This 
observation confirms the suppressor role of LATS1 in carcinogenesis in this first 
study on a large group of CRC patients.
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